6 results
DEF 14A
MLYS
Mineralys Therapeutics Inc
9 Apr 24
Definitive proxy
7:15am
to, with respect to age, gender, race, place of residence, and specialized experience;
experience relevant to our business industry and with relevant social … : Gender Identity
Directors
Part II: Demographic Background
Asian
White
Director Attendance at Annual Meetings
Although we do not have a formal policy
8-K
EX-10.1
MLYS
Mineralys Therapeutics Inc
8 Feb 24
Mineralys Therapeutics Announces $120 Million Private Placement Financing
4:41pm
the context otherwise requires, wherever used the singular shall include the plural, the plural the singular, the use of any gender shall be applicable to all
DRS/A
MLYS
Mineralys Therapeutics Inc
29 Dec 22
Draft registration statement (amended)
12:00am
to lorundrostat observed based on gender, race, age, or number of baseline antihypertensive medicines. Our analysis of the clinical results demonstrated … and pharmacodynamics of single and multiple ascending doses (MAD) of lorundrostat in healthy subjects, including the effect of gender and age on the pharmacokinetics
DRS/A
MLYS
Mineralys Therapeutics Inc
7 Dec 22
Draft registration statement (amended)
12:00am
. There was no consistent difference in clinical response to MLS-101 observed based on gender, race, age, or number of baseline antihypertensive medicines. Our analysis … of MLS-101 in healthy subjects, including the effect of gender and age on the pharmacokinetics of a single dose of MLS-101 in healthy subjects
DRS
0q5b1aoq
4 Nov 22
Draft registration statement
12:00am
- Prev
- 1
- Next